INFIGRATINIB, INFIGRATINIB, INFIGRATINIB, INFIGRATINIB, Infigratinib clinical trials

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

This study looks at a medicine called infigratinib for children with hypochondroplasia. It's an ongoing part of an earlier study, checking how safe the medicine is long-term and if it helps with growth and overall health.